Related Experiment Videos
Growth dynamics in cystic fibrosis
L Greco1, F Santamaria, D Salvatore
1Department of Paediatrics, 2nd School of Medicine, University of Naples, Italy.
Acta Paediatrica (Oslo, Norway : 1992)
|March 1, 1993
Summary
Cystic fibrosis patients exhibit pulsatile growth patterns, not linear ones. Clinical events in these patients frequently occur during the slowing phase of their growth velocity, suggesting personalized monitoring strategies.
Area of Science:
- Pediatrics
- Pulmonology
- Biostatistics
Background:
- Cystic fibrosis (CF) management requires understanding growth dynamics.
- Previous studies often assumed linear growth patterns in CF patients.
- Individual growth variability can impact clinical event prediction.
Purpose of the Study:
- To analyze the growth profiles of cystic fibrosis patients.
- To investigate the relationship between growth dynamics and clinical events.
- To determine if growth patterns correlate with adverse clinical outcomes.
Main Methods:
- Longitudinal analysis of height and weight data from 28 cystic fibrosis patients over at least three years.
- Three-month interval measurements to capture growth velocity.
- Plotting of height and weight velocity profiles to identify patterns.
- Correlation analysis between clinical events and phases of growth velocity.
Main Results:
- Growth patterns in cystic fibrosis patients were not linear but showed regular pulsatile height and weight velocity.
- A circannual rhythm was associated with the observed pulsatile growth rhythm.
- The majority of clinical events (71-82%) occurred during the descending phase of the growth velocity profile.
- Individual growth patterns demonstrated significant variability.
Conclusions:
- Cystic fibrosis patient growth is characterized by pulsatile velocity, not linear progression.
- Clinical events are significantly associated with the decelerating phase of individual growth velocity.
- Personalized surveillance and monitoring, timed with individual growth patterns, may enhance patient care and early detection of adverse events.